Previous close | 3.4200 |
Open | 3.4800 |
Bid | 3.4600 x 100 |
Ask | 3.5200 x 300 |
Day's range | 3.4500 - 3.6700 |
52-week range | 2.0100 - 6.1300 |
Volume | |
Avg. volume | 1,000,180 |
Market cap | 270.761M |
Beta (5Y monthly) | 0.98 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share. The gross proceeds from this offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissi
- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolRα-expressing cancers - - Compelling anti-leukemic activity of luvelta in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML treated under Compassionate Use shown in data presented at ASH 2023 - - Jane Chung promoted to President and Chief Operating Officer in November 2023 - - As of year-end 2023, Sutro had cash and investment
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences. Conference Details: Oppenheimer 34th Annual Healthcare Life Sciences ConferenceDate: February 13-14, 2024Location: Virtual TD Cowen 44th Annual Health